The severity of sevoflurane-induced malignant hyperthermia

Acta Anaesthesiologica Scandinavica

Volumn 56, Issue 3, 2012, Pages 351-356

  Migita, T ^a   Mukaida, K ^b   Kobayashi, M ^c   Hamada, H ^d   Kawamoto, M ^d  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b Hiroshima Pref Rehab Center   (Japan)

^c JA Hiroshima General Hospital   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLURANE; SEVOFLURANE;

ADOLESCENT; ADULT; ANESTHESIA COMPLICATION; CASE STUDY; CHILD; CLINICAL GRADING SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; MORTALITY; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHOOL CHILD; TACHYCARDIA;

ADOLESCENT; ADULT; ANESTHESIA, INHALATION; ANESTHETICS, INHALATION; BODY TEMPERATURE; CHILD, PRESCHOOL; CREATINE KINASE; DANTROLENE; DATABASES, FACTUAL; FEMALE; HUMANS; ISOFLURANE; JAPAN; MALE; MALIGNANT HYPERTHERMIA; METHYL ETHERS; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE RIGIDITY; MYOGLOBIN; NEUROMUSCULAR DEPOLARIZING AGENTS; SUCCINYLCHOLINE; TACHYCARDIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857239593     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2011.02573.x     Document Type: Review

References (21)

1. Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB,. Cardiac arrests and death associated with malignant hyperthermia in North America from 1987 to 2006. A report from the North America Malignant Hyperthermia Registry of the Malignant Hyperthermia Associatation of the United States. Anesthesiology 2008; 108: 603-611. (Pubitemid 351440580)
2. Rosenberg H, Davis M, James D, Pollock N, Stowell K,. Malignant Hyperthermia. Orphanet J Rare Dis 2007; 2: 21-34.
3. Hopkins PM,. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-128. (Pubitemid 30417227)
4. Stowell KM,. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008; 9: 1657-1672.
5. Carpenter D, Ringrose C, Leo V, Morris A, Robinson RL, Halsall PJ, Hopkins PM, Shaw MA,. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet 2009; 10: 104-115.
6. 2+ release from the sarcoplasmic reticulum of skeletal muscle. Anesthesiology 1999; 91: 179-186. (Pubitemid 29307351)
7. 2+-related functions of skinned skeletal muscle fibers from the guinea pig. Hiroshima J Med Sci 1991; 40: 9-13.
8. Otsuka H, Komura Y, Mayumi T, Yamamura T, Kemmotsu O, Mukaida K,. Malignant hyperthermia during sevoflurane anesthesia in a child with central core disease. Anesthesiology 1991; 75: 699-701.
9. Migita T, Mukaida K, Kawamoto M, Kobayashi M, Yuge O,. Fulminant-type malignant hyperthermia in Japan: cumulative analysis of 383 cases. J Anesth 2007; 21: 285-288. (Pubitemid 46692025)
10. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gonert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ,. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779. (Pubitemid 24128939)
11. Katoh T, Ikeda K,. The minimum alveolar concentration (MAC) of sevoflurane in humans. Anesthesiology 1987; 66: 301-303. (Pubitemid 17095252)
12. Katoh T, Ikeda K,. The minimum alveolar concentration of sevoflurane in children. Br J Anaesth 1992; 68: 139-141.
13. Drummond JC,. MAC for halothane, enflurane, and isoflurane in the New Zealand white rabbit: and a test for the validity of MAC determinations. Anesthesiology 1985; 62: 336-338. (Pubitemid 15101884)
14. Katoh T, Nakajima Y, Ikeda K,. MAC of sevoflurane is 1.71% -Objection to 'MAC of sevoflurane as 1.7% is wrong'. Clinical Anesthesia 1996; 20: 1611-1614. (in Japanese)
15. Stevens WC, Dolan WM, Gibbons RT, White A, Eger EI 2nd, Miller RD, Jong RH, Elashoff RM,. Minimum alveolar concentrations (MAC) of isoflurane with or without nitrous oxide in patients of various ages. Anesthesiology 1975; 45: 197-200.
16. Suyama H, Kawamoto M, Yuge O,. Prevention and treatment of malignant hyperthermia in certified training hospitals in Japan: a questionnaire. J Anesth 2002; 16: 207-210.
17. Maehara Y, Mukaida K, Kawamoto M, Yuge O,. An analysis of fetal malignant hyperthermia cases after 1990 in Japan (in Japanese). Nihon Rinsho Masui Gakkaishi (J Japan Soc Clin Anesth) 2000; 20: 385-390.
18. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB,. Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498-507.
19. Burkman JM, Posner KL, Domino KB,. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007; 106: 901-906. (Pubitemid 46684055)
20. 2+ regulation in skeletal muscle sarcoplasmic reticulum vesicles from young and mature rabbits. Pediatr Anesth 2009; 19: 1166-1174.
21. rd International symposium on malignant hyperthermia. Tokyo Heidelberg New York: Springer-Verlag, 1994: 49-56.